
Shanghai Bao Pharmaceuticals Co., Ltd.
2659.HKHKSEHealthcareBiotechnology
最新数据
HK$15.73
−HK$0.36 · -2.24%
2659.HK公司概览
盘中时间采用HKT。市场数据可能有所延迟。
公司概况
公司网站Shanghai Bao Pharmaceuticals Co., Ltd., a biotechnology company, engages in the research, development, and commercialization of pharmaceutical products in Mainland China. The company uses synthetic biology technology to develop and deliver recombinant biologic drugs. Its products include KJ017, a recombinant human hyaluronidase for subcutaneous drug delivery; KJ103, a recombinant immunoglobulin G (IgG)-degrading enzyme for IgG-mediated autoimmune diseases; and SJ02, a long-acting recombinant human follicle-stimulating hormone carboxyl-terminal peptide fusion protein (FSH CTP) for assisted reproduction. The company also develops KJ101, a recombinant human chymotrypsin developed through synthetic biology that is in Phase 2 clinical trials; KJ015, a bispecific anti HER2 antibody; BJ007, a subcutaneous formulation of ceftriaxone sodium for the treatment of bacterial infections; BJ009, a first generation cephalosporin antibiotic for treating bacterial infections, including of the skin, bones, joints, reproductive organs, blood, heart valves, respiratory tract, biliary tract, and urinary tract; and SJ04, a recombinant human chorionic gonadotropin (hCG) that can be used in assisted reproductive procedures to accelerate follicle maturation and induce ovulation. These product candidates are in Phase 1 clinical trials. In addition, it is developing BJ045, a subcutaneously administered anti CD20 antibody; BJ047, a subcutaneously administered anti CD154 antibody; BJ008, a subcutaneous formulation of cefoperazone sodiumsulbactam sodium to treat bacterial infections; and BJ044, a serine protease inhibitor with broad anti inflammatory properties. These product candidates are in the preclinical stage. Further, the company licenses its intellectual property and other deliverables and provides technical services. Shanghai Bao Pharmaceuticals Co., Ltd. was founded in 2019 and is based in Shanghai, China.
- 行业
- Biotechnology
- 部门
- Healthcare
- 总部
- CN
- 首席执行官
- Wang Zheng
- 上市以来
- 2025年12月10日
- 雇员
- 354
市场位置
日内区间
当前HK$15.73,
52周区间
当前HK$15.73,
- 开盘价
- HK$16.12
- 前收盘价
- HK$16.09
- 成交量
- 20.11万
- 0.08× 平均值
- 平均成交量
- 266.66万
- 日均成交量
- 市值
- 24.02亿 HKD
- 贝塔
- 0.92
- 市场参考 1
- 50天平均值
- HK$17.9348
- 低于平均水平-12.29%
- 200天平均值
- HK$67.3497
- 低于平均水平-76.64%
2659.HK同业公司
持有2659.HK的ETF
报告持有此股票敞口的交易所交易基金。
iShares Core MSCI Emerging Markets ETFIEMG42.91万0.00%1600.01亿 USD0.09%US$80.655-1.12%
iShares MSCI China Small-Cap ETFECNS2.77万0.04%6648.31万 USD0.59%US$28.92-1.53%
State Street SPDR S&P China ETFGXC1.16万0.00%4.75亿 USD0.59%US$90.315-1.25%
State Street SPDR Portfolio MSCI Global Stock Market ETFSPGM67360.00%17.41亿 USD0.09%US$87.54-0.30%
iShares Core 80/20 Aggressive Allocation ETFAOA775.640.00%32.86亿 USD0.19%US$98.805-0.21%
iShares Core 60/40 Balanced Allocation ETFAOR676.490.00%37.53亿 USD0.20%US$69.765-0.12%
iShares Core 40/60 Moderate Allocation ETFAOM219.070.00%17.81亿 USD0.20%US$49.75-0.04%
iShares Core 30/70 Conservative Allocation ETFAOK73.770.00%7.99亿 USD0.20%US$41.305+0.01%
iShares Core MSCI Emerging Markets ETFIEMG- 市场价值
- 42.91万
- 重量
- 0.00%
- AUM
- 1600.01亿 USD
- 费用率
- 0.09%
- 价格 / 1日
- US$80.655-1.12%
iShares MSCI China Small-Cap ETFECNS- 市场价值
- 2.77万
- 重量
- 0.04%
- AUM
- 6648.31万 USD
- 费用率
- 0.59%
- 价格 / 1日
- US$28.92-1.53%
State Street SPDR S&P China ETFGXC- 市场价值
- 1.16万
- 重量
- 0.00%
- AUM
- 4.75亿 USD
- 费用率
- 0.59%
- 价格 / 1日
- US$90.315-1.25%
State Street SPDR Portfolio MSCI Global Stock Market ETFSPGM- 市场价值
- 6736
- 重量
- 0.00%
- AUM
- 17.41亿 USD
- 费用率
- 0.09%
- 价格 / 1日
- US$87.54-0.30%
iShares Core 80/20 Aggressive Allocation ETFAOA- 市场价值
- 775.64
- 重量
- 0.00%
- AUM
- 32.86亿 USD
- 费用率
- 0.19%
- 价格 / 1日
- US$98.805-0.21%
iShares Core 60/40 Balanced Allocation ETFAOR- 市场价值
- 676.49
- 重量
- 0.00%
- AUM
- 37.53亿 USD
- 费用率
- 0.20%
- 价格 / 1日
- US$69.765-0.12%
iShares Core 40/60 Moderate Allocation ETFAOM- 市场价值
- 219.07
- 重量
- 0.00%
- AUM
- 17.81亿 USD
- 费用率
- 0.20%
- 价格 / 1日
- US$49.75-0.04%
iShares Core 30/70 Conservative Allocation ETFAOK- 市场价值
- 73.77
- 重量
- 0.00%
- AUM
- 7.99亿 USD
- 费用率
- 0.20%
- 价格 / 1日
- US$41.305+0.01%
继续GoAI的研究
在 GoAI 中研究2659.HKresearch.disclaimer





